Jawed Fareed, PhD, DSc, Rodger L. Bick, MD, PhD, Gundu Rao, PhD, Samuel Z. Goldhaber, MD, Arthur Sasahara, MD, Harry L. Messmore, MD, Debra A. Happensteadt, PhD, and Andrew Nicolaides, MD, on behalf of the IACATH, IUA, SASAT, and NATF* translate into their safety and efficacy profiles in a given clinical indication. Therefore, the United States Food and Drug Administration (FDA) and other regulatory bodies consider each of the commercially available LMWHs as a distinct drug and require clinical validation for the approval of each of these in specific indications. The introduction of generic versions of the branded LMWHs has challenged the regulatory bodies to develop specific guidelines for their approval. The current guidelines for generic drug approval are not adequate because of the complex nature of the LMWHs due to biologic origins and chemical modifications of a polycomponent mixture of glycosaminoglycans.
Although the incidence of HIT is rare with the use of LMWHs and heparinomimetics such as fondaparinux and idraparinux when used for prophylactic and therapeutic indications, these agents are capable of generating antibodies to heparin-PF4 complex, which are measurable by using immunologic methods. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The relative prevalence of these antibodies is method-dependent owing to different capturing probes. Moreover, the relative proportion of antibody subtypes (immunoglobulin G, A, and M) differ from product to product. [12] [13] [14] Up to 20% of the patients treated with LMWHs generate these antibodies. The pathophysiologic role of these antibodies remains unknown at this time. [15] [16] [17] [18] [19] [20] However, this immunogenic response is comparable to autoimmune responses observed in the case of the antiphospholipid syndrome. Additional data are needed to identify the role of these antibodies in various pathologic states and their impact on clinical outcomes.
The FDA has been visionary in identifying the immunogenicity of LMWHs as an important criterion to differentiate and demonstrate the bioequivalence H eparin-induced thrombocytopenia (HIT) is a catastrophic adverse reaction associated with the use of heparins and related products. Although the incidence of HIT with low-molecularweight heparins (LMWHs) is much lower than with unfractionated heparin (UFH), 1 these agents are capable of triggering immunogenic responses in 10% to 20% of the patients treated for different indications. The generation of these antibodies depends on the dosage, duration of treatment, patient population, and underlying comorbidities. Differences in the immunogenic responses among different branded LMWHs have been noted. These differences are due to the structural composition of the LMWH and the interactions with endogenous platelet factor 4 (PF4) and other proteins.
Low-molecular-weight heparins have been differentiated on the basis of several biophysical, biochemical, and pharmacologic properties. These differences 
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of generic LMWHs to the branded products. The agency has made a determination that the immunogenic responses of LMWHs occur because of the interactions of the components of the generic products with PF4 and other proteins, that result in the formation of complexes that lead to an immunogenic response. Therefore, if a generic product has identical composition and similar proportion of the oligosaccharide components as the branded product, then the generic product would exhibit a similar quantitative and qualitative immunogenic profile. Such a bioequivalence can only be demonstrated in well-designed, population-balanced clinical trials that include critically ill patients with multiple pathogenic etiologies. The FDA is to be commended for this very clear directive. This underscores the concerns on the use of biologics that have multiple components and mechanisms of action.
Although the generic LMWHs may exhibit similar molecular profile and anti-factor Xa potency, some of the currently available generic versions of LMWHs have been found to differ in their biochemical and pharmacologic profiles. 21 Therefore, the additional recommendation to profile these agents for other biologic actions and their interactions with cells beyond the immunogenic profiling should also be taken into consideration to assure therapeutic equivalence. As the different regulatory and professional organizations are moving ahead in developing recommendations for the therapeutic and generic interchange of these drugs in different indications, the FDA's action to require immunogenic profiling of these drugs is not only timely but also prudent in establishing approval guidelines which will have an International impact.
Heparin and LMWHs are also capable of binding to several other endogenous proteins. It is likely that these interactions can also result in the generation of neoepitopes. The physiologic implications of such responses are not known. Most of the immunogenic response data currently available are based on the use of 2 methods that use enzyme-linked immunosorbent assay. 22 With the advances in technology, several other methods have recently become available. Therefore, it is important to have standardized methods to compare the immunogenic potential using valid methodologies with particular reference to the specific antibodies to be profiled. At the present time, the immunogenic profiling is focused on the antibodies that are generated against the PF4 neoantigen formed upon complexation of heparin oligosaccharides and PF4.
The International Academy of Clinical and Applied Thrombosis and Hemostasis (IACATH), the International Union of Angiology (IUA), the South Asian Society of Atherosclerosis and Thrombosis (SASAT), and the North American Thrombosis Forum (NATF) will review and consider endorsing this requirement in conjunction with the white paper that is currently being prepared on the International Summit on Generic Antithrombotic drugs that was held in New Delhi under their auspices on October 12, 2007. This white paper will be published in the journals of the sponsoring societies and posted on their respective Web sites.
